Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GEMTUZUMAB OZOGAMICIN Cause Disease progression? 21 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Disease progression have been filed in association with GEMTUZUMAB OZOGAMICIN (Mylotarg). This represents 1.2% of all adverse event reports for GEMTUZUMAB OZOGAMICIN.

21
Reports of Disease progression with GEMTUZUMAB OZOGAMICIN
1.2%
of all GEMTUZUMAB OZOGAMICIN reports
15
Deaths
9
Hospitalizations

How Dangerous Is Disease progression From GEMTUZUMAB OZOGAMICIN?

Of the 21 reports, 15 (71.4%) resulted in death, 9 (42.9%) required hospitalization, and 6 (28.6%) were considered life-threatening.

Is Disease progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GEMTUZUMAB OZOGAMICIN. However, 21 reports have been filed with the FAERS database.

What Other Side Effects Does GEMTUZUMAB OZOGAMICIN Cause?

Febrile neutropenia (412) Pyrexia (138) Sepsis (122) Thrombocytopenia (117) Venoocclusive liver disease (117) Off label use (88) Drug ineffective (87) Death (81) Bone marrow failure (80) Neutropenia (68)

What Other Drugs Cause Disease progression?

RITUXIMAB (7,282) CYCLOPHOSPHAMIDE (7,100) DOXORUBICIN (6,165) VINCRISTINE (5,252) PREDNISONE (5,096) BEVACIZUMAB (4,653) DEXAMETHASONE (4,545) CARBOPLATIN (4,538) CAPECITABINE (3,808) ETOPOSIDE (3,776)

Which GEMTUZUMAB OZOGAMICIN Alternatives Have Lower Disease progression Risk?

GEMTUZUMAB OZOGAMICIN vs GEMZAR GEMTUZUMAB OZOGAMICIN vs GENTAMICIN GEMTUZUMAB OZOGAMICIN vs GEODON GEMTUZUMAB OZOGAMICIN vs GILENYA GEMTUZUMAB OZOGAMICIN vs GILOTRIF

Related Pages

GEMTUZUMAB OZOGAMICIN Full Profile All Disease progression Reports All Drugs Causing Disease progression GEMTUZUMAB OZOGAMICIN Demographics